Hyperkalemia Prevention and Management in Chronic Kidney Disease
Hyperkalemia is a significant risk of medications that slow progression of chronic kidney disease. Oftentimes these medications or their optimal doses are avoided as a means to mitigate the risk of hyperkalemia, withholding the full potential benefit for our patients. Complicating this problem is the reality that evidence-based guidelines for managing hyperkalemia in patients with chronic kidney disease are sparse. In this module, we will cover risks of hyperkalemia, describe current guidelines that discuss hyperkalemia in CKD, and summarize a patient-centered approach to prevent and treat hyperkalemia.
By the end of this module, learners will be able to:
- Describe risk factors for hyperkalemia in patients with CKD and the pharmacologic therapies associated with development of hyperkalemia
- Differentiate the mechanism of action, timing of the effect on potassium lowering, and drug interactions with patiromer and sodium zirconium cyclosilicate
- Develop a plan to prevent and manage hyperkalemia that includes dietary considerations and use of potassium binding agents using a patient case
- Analyze the advantages and disadvantages of a low potassium diet for the treatment and prevention of hyperkalemia in a patient with CKD
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Katie Cardone, PharmD, BCACP, FNKF, FASN, FCCP - Grants/Research Support [Merck & Co], Consultant [Vifor, Otsuka], Honorarium [Pharmacy Times]
- Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK, Wolters-Kluwer (Lexicorp)]
- Wendy St. Peter, FCCP, FASN, FNKF - Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for .75 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded .75 contact hours of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for .75 contact hours. UAN: JA4008105-9999-23-016-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
